COVID-19 | Covaxin vaccine approved by the WHO has an efficacy of 78%

The World Health Organization (WHO) granted this Wednesday an urgent homologation of the vaccine against COVID-19 Covaxin, from the Indian laboratory Bharat Biotech.

SIGHT: COVID-19 | About alcohol in shoes and other little or no effective care in this pandemic

This vaccine is recommended for everyone from 18 years of age.

Requires two doses four weeks apart and “It is especially adapted to countries with limited resources because , according to a WHO statement.

SIGHT: US Authorizes Pfizer Vaccine for Children Ages 5 to 11

It is the first vaccine developed and manufactured entirely in India to be approved by the UN organization.

It thus joins Pfizer / BioNTech, Moderna, AstraZeneca, Johnson & Johnson, Sinopharm and Sinovac in the list of vaccines against COVID-19

SIGHT: COVID-19 | What is known about possible hair loss after infection and the vaccine?

Certification by the WHO facilitates international recognition of the vaccine and, above all, allows it to be used by UN agencies and the Covax system, created for the poorest countries.

• US Authorizes Pfizer Vaccine for Children Ages 5 to 11
• COVID-19 | About alcohol in shoes and other little or no effective care in this pandemic
• COVID-19 | What is known about possible hair loss after infection and the vaccine?
• COVID-19 | How do patients who lost it to the coronavirus regain their sense of smell?
• COVID-19 | How effective is the third dose of Pfizer against the Delta variant?
• “Vax” is the word of the year in English, according to the Oxford Dictionary
• The utopia of COVID-19 zero, by Elmer Huerta
• COVID-19 | EMA Says “There is Not Sufficient Evidence” Vaccines Cause Multisystem Inflammatory Syndrome
• COVID-19 | Vaccines protect against the Delta variant, but do not stop contagion within the home
• Sotrovimab antibody reduces risk of hospitalization or death from COVID-19 by 79%
• Fluvoxamine Drug Reduces COVID-19 Hospitalizations, Study Finds
• People with a history of cancer are at increased risk of complications from COVID-19
• Why do some healthy young people get severe COVID-19?
• COVID-19 | Merck announces that a generic version of its pill would be distributed in poor countries
• The world has not learned from the COVID-19 pandemic, warn WHO and World Bank
• COVID-19 | Halving the first dose of AstraZeneca improves its potency, study finds
• More than 80% of COVID-19 patients are at risk of malnutrition when leaving the hospital
• What does the WHO say about the end of the COVID-19 pandemic?
• COVID-19 | Scientists discover a method to block coronavirus infection
• European Medicines Agency Launches Accelerated Review of Merck’s COVID-19 Pill
• Moderna announces that its vaccine has strong efficacy in children aged 6 to 11 years
• The Answers for a Safe Return to School, by Elmer Huerta
• COVID-19 | Everything you need to know about the effects of vaccines
• Face-to-face classes at universities: what measures should be taken to avoid contagion?

Follow us on twitter:

!function(d,s,id){var js,fjs=d.getElementsByTagName(s)[0],p=/^http:/.test(d.location)?’http’:’https’;if(!d.getElementById(id)){js=d.createElement(s);js.id=id;js.src=p+’://platform.twitter.com/widgets.js’;fjs.parentNode.insertBefore(js,fjs);}}(document, ‘script’, ‘twitter-wjs’);

.

Deshawn